Disclosed are a heterocyclic compound represented by Formula 1-1 or 1-2,

##STR00001## wherein, in Formulae 1-1 and 1-2, X.sub.1, CY.sub.1 to CY.sub.3, R.sub.1 to R.sub.3, and a1 to a3, are the same as described in the specification. Also disclosed is an organic light-emitting device including the same.

The present invention relates to a method for producing an InP-based quantum dot precursor from a phosphorus source and an indium source, in which a silylphosphine compound represented by the following Formula (1) with a content of a compound represented by the following Formula (2) of 0.3 mol % or less is used as the phosphorus source. Further, the present invention provides a method for producing an InP-based quantum dot comprising heating an InP quantum dot precursor to a temperature of 200° C. or more and 350° C. or less to obtain an InP quantum dot. ##STR00001##
(R is as defined in the specification.)

Electrolytes and electrolyte additives for energy storage devices comprising phosphazene based compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte comprising at least two electrolyte co-solvents, wherein at least one electrolyte co-solvent comprises a phosphazene based compound.

Electrolytes and electrolyte additives for energy storage devices comprising phosphazene based compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte comprising at least two electrolyte co-solvents, wherein at least one electrolyte co-solvent comprises a phosphazene based compound.

The present disclosure provides a boron-heterocyclic compound having a structure represented by Chemical Formula 1, in which L.sub.1 and L.sub.2 are each independently selected from a single bond, C6-C30 aryl, C6-C30 fused aryl, C4-C30 heteroaryl, or C4-C30 fused heteroaryl; and R.sub.1 and R.sub.2 are each independently selected from carbazolyl and derivative groups thereof, acridinyl and derivative groups thereof, and diarylamino and derivative groups thereof. In an embodiment, the boron-heterocyclic structure is suitable for use not only as an electron acceptor group but also as a linking group. By linking a group having a large steric hindrance to the boron atom of the boron-heterocyclic ring, the compound molecules are prevented or limited from aggregating, and thus a π-aggregation or excimer formed by direct accumulation of conjugate planes is avoided or reduced, thereby improving luminous efficiency. The present disclosure further provides a display panel and a display apparatus containing the compound. ##STR00001##

The present disclosure provides a boron-heterocyclic compound having a structure represented by Chemical Formula 1, in which L.sub.1 and L.sub.2 are each independently selected from a single bond, C6-C30 aryl, C6-C30 fused aryl, C4-C30 heteroaryl, or C4-C30 fused heteroaryl; and R.sub.1 and R.sub.2 are each independently selected from carbazolyl and derivative groups thereof, acridinyl and derivative groups thereof, and diarylamino and derivative groups thereof. In an embodiment, the boron-heterocyclic structure is suitable for use not only as an electron acceptor group but also as a linking group. By linking a group having a large steric hindrance to the boron atom of the boron-heterocyclic ring, the compound molecules are prevented or limited from aggregating, and thus a π-aggregation or excimer formed by direct accumulation of conjugate planes is avoided or reduced, thereby improving luminous efficiency. The present disclosure further provides a display panel and a display apparatus containing the compound. ##STR00001##

The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).

A heterocyclic compound represented by Formula 1: ##STR00001##
wherein A.sub.1 in Formula 1 is selected from groups represented by Formulae 1-1 to 1-7, ##STR00002##
and an organic light-emitting device including the same.

A heterocyclic compound represented by Formula 1: ##STR00001##
wherein A.sub.1 in Formula 1 is selected from groups represented by Formulae 1-1 to 1-7, ##STR00002##
and an organic light-emitting device including the same.

Gold (I) complexes that can absorb light in the near-UV and/or visible regions and methods of making and using thereof are described. These gold (I) complexes have photochemical reactivities, such as strong absorption of near-UV and/or visible light, quenching rate constants ≥3.5×10.sup.5 s.sup.−1, etc., that allow them to catalyze photoredox reactions, such as homocoupling of organic halides (e.g. alkyl halides and aryl halides), alkylation of 2-phenyl-1,2,3,4-tetrahydroisoquinoline, cyclization of indoles, reductive dehalogenation of aryl halides, and/or C—H bonds cleavage, under near-UV and/or visible light. The product of a photo-induced organic reaction catalyzed by the gold (I) complexes described herein can have a yield that is higher than the yield of the same product formed from the same reaction under the same reaction conditions, using the same loading or a higher loading of [Au.sub.2(μ-dppm).sub.2](Cl).sub.2, [Ru(bpy).sub.3](Cl).sub.2, and/or [fac-Ir(ppy).sub.3] compared to the loading of the one or more gold (I) complex(es).